» Articles » PMID: 26537124

Acute Disruption of Glucagon Secretion or Action Does Not Improve Glucose Tolerance in an Insulin-deficient Mouse Model of Diabetes

Overview
Journal Diabetologia
Specialty Endocrinology
Date 2015 Nov 6
PMID 26537124
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Aims/hypothesis: Normal glucose metabolism depends on pancreatic secretion of insulin and glucagon. The bihormonal hypothesis states that while lack of insulin leads to glucose underutilisation, glucagon excess is the principal factor in diabetic glucose overproduction. A recent study reported that streptozotocin-treated glucagon receptor knockout mice have normal glucose tolerance. We investigated the impact of acute disruption of glucagon secretin or action in a mouse model of severe diabetes by three different approaches: (1) alpha cell elimination; (2) glucagon immunoneutralisation; and (3) glucagon receptor antagonism, in order to evaluate the effect of these on glucose tolerance.

Methods: Severe diabetes was induced in transgenic and wild-type mice by streptozotocin. Glucose metabolism was investigated using OGTT in transgenic mice with the human diphtheria toxin receptor expressed in proglucagon producing cells allowing for diphtheria toxin (DT)-induced alpha cell ablation and in mice treated with either a specific high affinity glucagon antibody or a specific glucagon receptor antagonist.

Results: Near-total alpha cell elimination was induced in transgenic mice upon DT administration and resulted in a massive decrease in pancreatic glucagon content. Oral glucose tolerance in diabetic mice was neither affected by glucagon immunoneutralisation, glucagon receptor antagonism, nor alpha cell removal, but did not deteriorate further compared with mice with intact alpha cell mass.

Conclusions/interpretation: Disruption of glucagon action/secretion did not improve glucose tolerance in diabetic mice. Near-total alpha cell elimination may have prevented further deterioration. Our findings support insulin lack as the major factor underlying hyperglycaemia in beta cell-deficient diabetes.

Citing Articles

The impact of glucagon to support postabsorptive glucose flux and glycemia in healthy rats and its attenuation in male Zucker diabetic fatty rats.

Estes S, Shiota C, OBrien T, Printz R, Shiota M Am J Physiol Endocrinol Metab. 2024; 326(3):E308-E325.

PMID: 38265288 PMC: 11193518. DOI: 10.1152/ajpendo.00192.2023.


α-cell electrophysiology and the regulation of glucagon secretion.

Gao R, Acreman S, Ma J, Abdulkader F, Wendt A, Zhang Q J Endocrinol. 2023; 258(2).

PMID: 37159865 PMC: 10326640. DOI: 10.1530/JOE-22-0295.


The role of preproglucagon peptides in regulating β-cell morphology and responses to streptozotocin-induced diabetes.

Arble D, Hutch C, Hafner H, Stelmak D, Leix K, Sorrell J Am J Physiol Endocrinol Metab. 2023; 324(3):E217-E225.

PMID: 36652401 PMC: 9970646. DOI: 10.1152/ajpendo.00152.2022.


The past, present, and future physiology and pharmacology of glucagon.

Capozzi M, DAlessio D, Campbell J Cell Metab. 2022; 34(11):1654-1674.

PMID: 36323234 PMC: 9641554. DOI: 10.1016/j.cmet.2022.10.001.


Neprilysin Inhibition Increases Glucagon Levels in Humans and Mice With Potential Effects on Amino Acid Metabolism.

Kjeldsen S, Hansen L, Esser N, Mongovin S, Winther-Sorensen M, Galsgaard K J Endocr Soc. 2021; 5(9):bvab084.

PMID: 34337276 PMC: 8317634. DOI: 10.1210/jendso/bvab084.


References
1.
Wang M, Yan H, Shi Z, Evans M, Yu X, Lee Y . Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway. Proc Natl Acad Sci U S A. 2015; 112(8):2503-8. PMC: 4345619. DOI: 10.1073/pnas.1424934112. View

2.
Baldissera F, Holst J, Knuhtsen S, Hilsted L, NIELSEN O . Oxyntomodulin (glicentin-(33-69)): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs. Regul Pept. 1988; 21(1-2):151-66. DOI: 10.1016/0167-0115(88)90099-7. View

3.
Kelly R, Garhyan P, Raddad E, Fu H, Lim C, Prince M . Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. Diabetes Obes Metab. 2015; 17(4):414-22. DOI: 10.1111/dom.12446. View

4.
Katz J, Golden S, Wals P . Stimulation of hepatic glycogen synthesis by amino acids. Proc Natl Acad Sci U S A. 1976; 73(10):3433-7. PMC: 431129. DOI: 10.1073/pnas.73.10.3433. View

5.
Kodra J, Jorgensen A, Andersen B, Behrens C, Brand C, Christensen I . Novel glucagon receptor antagonists with improved selectivity over the glucose-dependent insulinotropic polypeptide receptor. J Med Chem. 2008; 51(17):5387-96. DOI: 10.1021/jm7015599. View